Clinical Trial Detail

NCT ID NCT02355431
Title INCB039110 in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Incyte Corporation
Indications

lung non-small cell carcinoma

Therapies

Erlotinib

Itacitinib

Age Groups: adult

No variant requirements are available.